| Sep 18 |
Organon to acquire Roivant company Dermavant for $1.2B
|
| Sep 18 |
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
|
| Sep 10 |
Roivant creates Pulmovant to house lung disorder drug licensed from Bayer
|
| Sep 10 |
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
|
| Sep 10 |
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
|
| Sep 9 |
Immunovant stock falls 8% amid Graves' disease program update
|
| Sep 9 |
Roivant Provides Update on Graves’ Disease Development Program
|
| Sep 4 |
The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy
|
| Aug 22 |
Shareholders In Roivant Sciences (NASDAQ:ROIV) Should Look Beyond Earnings For The Full Story
|
| Aug 22 |
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
|
